Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$37.83 USD
+1.08 (2.94%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $37.58 -0.25 (-0.66%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTGX 37.83 +1.08(2.94%)
Will PTGX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy
Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
4 Stocks to Buy for Attractive Earnings Acceleration
Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware
4 Must-Buy Stocks for Remarkable Earnings Acceleration
Other News for PTGX
Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024
Protagonist Therapeutics set to join S&P SmallCap 600
Protagonist Therapeutics Set to Join S&P SmallCap 600
Fly Intel: After-Hours Movers
Protagonist Therapeutics to replace Encore Wire in S&P 600 at open on 7/3